OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
OBCK59

Ottobock SE & Co KgaA

Medical Equipment, Supplies & DistributionVerified

Ottobock's capital structure is characterized by a debt-to-equity ratio of 2.69, indicating a significant reliance on debt financing. The company's liquidity position is moderate, with a current ratio of 0.95 and only 90.4 million EUR in cash and equivalents, which is insufficient to cover its 1.05 billion EUR in long-term debt. This suggests a potential liquidity risk if short-term obligations exceed available cash. In terms of profitability, Ottobock's return on equity (ROE) of 23.12% is strong, outperforming the typical industry benchmark for ROE in the medical equipment sector. However, its return on assets (ROA) of 4.4% is in line with the industry median, indicating that the company is not generating exceptional returns relative to its asset base. Gross profit of 886.5 million EUR and operating income of 199.8 million EUR reflect a healthy margin structure, but the net income of 90.2 million EUR suggests that interest and other expenses are consuming a significant portion of operating profits. Geographically, Ottobock's revenue is not disclosed by segment or region in the available data, but the company operates globally in the medical equipment and supplies market. The lack of detailed geographic breakdown limits the ability to assess exposure to specific markets or regions. The company's revenue concentration is not explicitly stated, but the absence of segment-specific data implies a need for further investigation into potential overreliance on a single market or product line. Ottobock's growth trajectory is not explicitly outlined in the available data, but the company's operating cash flow of 332.7 million EUR and free cash flow of 117.9 million EUR suggest a capacity to fund operations and potentially reinvest in the business. Capital expenditures of -108.7 million EUR indicate that the company is investing in its infrastructure, which could support future growth. Analysts have provided a mean price target of 81.25 EUR and a median price target of 83.00 EUR, with a mean recommendation of 1.75, indicating a generally positive outlook. The risk assessment for Ottobock highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could pose a challenge in maintaining liquidity if cash flow from operations is disrupted. There is no indication of dilution risk in the near term, as the number of shares outstanding has not changed between basic and diluted shares. Recent events and filings have not been disclosed in the available data, so the impact of any recent developments on Ottobock's financial position or strategic direction cannot be assessed.

30-day price · OBCK+0.30 (+0.5%)
Low$52.20High$65.00Close$56.20As of25 May, 00:00 UTC
Profile
CompanyOttobock SE & Co KgaA
TickerOBCK.DE
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Ottobock SE & Co KgaA develops and distributes medical equipment and supplies, primarily serving the healthcare services and equipment industry.

Classification. Ottobock is classified in the Healthcare Services & Equipment business sector under the Medical Equipment, Supplies & Distribution industry with a confidence level of 0.92.

Ottobock's capital structure is characterized by a debt-to-equity ratio of 2.69, indicating a significant reliance on debt financing. The company's liquidity position is moderate, with a current ratio of 0.95 and only 90.4 million EUR in cash and equivalents, which is insufficient to cover its 1.05 billion EUR in long-term debt. This suggests a potential liquidity risk if short-term obligations exceed available cash. In terms of profitability, Ottobock's return on equity (ROE) of 23.12% is strong, outperforming the typical industry benchmark for ROE in the medical equipment sector. However, its return on assets (ROA) of 4.4% is in line with the industry median, indicating that the company is not generating exceptional returns relative to its asset base. Gross profit of 886.5 million EUR and operating income of 199.8 million EUR reflect a healthy margin structure, but the net income of 90.2 million EUR suggests that interest and other expenses are consuming a significant portion of operating profits. Geographically, Ottobock's revenue is not disclosed by segment or region in the available data, but the company operates globally in the medical equipment and supplies market. The lack of detailed geographic breakdown limits the ability to assess exposure to specific markets or regions. The company's revenue concentration is not explicitly stated, but the absence of segment-specific data implies a need for further investigation into potential overreliance on a single market or product line. Ottobock's growth trajectory is not explicitly outlined in the available data, but the company's operating cash flow of 332.7 million EUR and free cash flow of 117.9 million EUR suggest a capacity to fund operations and potentially reinvest in the business. Capital expenditures of -108.7 million EUR indicate that the company is investing in its infrastructure, which could support future growth. Analysts have provided a mean price target of 81.25 EUR and a median price target of 83.00 EUR, with a mean recommendation of 1.75, indicating a generally positive outlook. The risk assessment for Ottobock highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could pose a challenge in maintaining liquidity if cash flow from operations is disrupted. There is no indication of dilution risk in the near term, as the number of shares outstanding has not changed between basic and diluted shares. Recent events and filings have not been disclosed in the available data, so the impact of any recent developments on Ottobock's financial position or strategic direction cannot be assessed.
Key takeaways
  • Ottobock has a strong ROE of 23.12%, indicating effective use of equity capital.
  • The company's liquidity position is moderate, with a current ratio of 0.95 and insufficient cash to cover long-term debt.
  • Analysts have a generally positive outlook, with a mean price target of 81.25 EUR and a median price target of 83.00 EUR.
  • Ottobock's capital expenditures suggest ongoing investment in infrastructure, which could support future growth.
  • The company's net cash position is negative after accounting for total debt, indicating a potential liquidity risk.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue$1.68B
Gross profit$886.5M
Operating income$199.8M
Net income$90.2M
R&D
SG&A
D&A
SBC
Operating cash flow$332.7M
CapEx-$108.7M
Free cash flow$117.9M
Total assets$2.05B
Total liabilities$1.66B
Total equity$390.1M
Cash & equivalents$90.4M
Long-term debt$1.05B
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$390.1M
Net cash-$960.7M
Current ratio0.9
Debt/Equity2.7
ROA4.4%
ROE23.1%
Cash conversion3.7%
CapEx/Revenue-6.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricOBCKActivity
Op margin11.9%3.9% medp25 -31.3% · p75 14.4%above median
Net margin5.4%2.4% medp25 -30.5% · p75 11.1%above median
Gross margin52.8%46.7% medp25 28.2% · p75 63.1%above median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-6.5%-4.8% medp25 -11.6% · p75 -2.4%below median
Debt / equity269.0%17.9% medp25 2.7% · p75 52.2%top quartile
Observations
IR observations
Mean price target81.25 EUR
Median price target83.00 EUR
High price target92.00 EUR
Low price target66.00 EUR
Mean recommendation1.75 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count4.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate2.98 EUR
Last actual EPS1.41 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 20:30 UTC#f28139e8
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 19:55 UTCJob: 49db2dcd